Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Smith, BD
- Papayannidis, C
- Heuser, M
- Sekeres, MA
- Oriol, A
- Schiller, GJ
- Candoni, A
- Jamieson, CHM
- Hoang, CJ
- Ma, W
- Zeremski, M
- O'Connell, A
- Chan, G
- Cortes, JE
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Smith,BD,Papayannidis,C,Heuser,M,Montesinos,P,Sekeres,MA,Oriol,A,Schiller,GJ et al. Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2019. Chicago-IL. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2019.
Portal de investigación